Previous 10 | Next 10 |
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2021. Net loss for the third quarter ended Septem...
Cassava stock increased 49% last Thursday as a short attack fell on deaf ears in favor of a positive report from the Journal of Neuroscience. The short thesis on simufilam may or may not have merit. The problem is shorts misunderstood market forces and are setting themselves up to be ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re going to invest in a biotechnology company like Cassava Sciences (NASDAQ: SAVA ), don’t expect slow and steady returns. SAVA stock isn’t for the faint of heart, or the risk-averse. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Based on a very disturbing new report issued about Cassava (NASDAQ: SAVA ), I have sold the vast majority of my shares of SAVA stock. And until the company refutes most or all of the allegations contained in the repor...
Bloomberg reports this week that the VIX (the CBOE Volatility Index) is rallying with the S&P 500 in a rare way over the past few weeks. And recent analysis from Susquehanna suggests that this is not because people are bidding up put option contract prices out of valuation jitters but bid...
In response to those questioning Cassava Sciences' credibility, the company released a statement from the Journal of Neuroscience confirming the accuracy of "its" Western blot slides. The stated mechanisms behind Cassava Sciences' simufilam would not have led to improvements in cognit...
Central to Cassava’s hypothesis requires amyloid beta-42 to induce an altered conformation of structural protein filamin A and that sumifilam restores altered filmin A back to its native state. Researchers have demonstrated that mutations that cause familial AD, amyloid beta-40...
Are These The Best Biotech Stocks To Buy Right Now? As we begin another week of trading, the stock market continues to break new highs. In light of this, biotech stocks continue to draw traction among investors. After all, this is an industry that constantly has new developm...
The emerging dominance of COVID-19 pills and concerning outlook for vaccine makers dominated healthcare headlines this week amid a flurry of earnings reports. Yet, with an over twofold rise in value, a clinical-stage Alzheimer’s drug developer outshone them all. However, pressure on va...
On Nov 4, Cassava Sciences issued a PR which headline reads, 'Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences' And the sub-heading: It states, "No evidence of data manipulation was found for Western blot data...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...